Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Real-world outcomes of autoSCT for multiple myeloma in the first-line setting

In this video, Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses first-line treatment options involving autologous stem cell transplant (autoSCT) for patients with multiple myeloma (MM). Dr Richter emphasizes the importance of real-world data and discusses how findings from trials can be applied in a clinical setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Secura Bio: Consultancy, Honoraria; Takeda: Consultancy; Oncopeptides: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.